SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease.

Paul DuengelhoefJohannes Hartl Darius F RuetherSilja SteinmannThomas T BrehmJan Philipp WeltzschFabian GlaserG M SchaubMartina SterneckMarcial SebodeChristina Weiler-NormannMarylyn M AddoMarc LütgehetmannFriedrich HaagChristoph SchrammJulian Schulze Zur WieschAnsgar W Lohse

Published in: United European gastroenterology journal (2022)

Patients with AIH show an increased SARS-CoV-2 infection rate as well as an impaired B- and T-cell response to SARS-CoV-2 vaccine compared to PBC and PSC patients, even in the absence of immunosuppression. Thus, antibody responses to vaccination in AIH patients need to be monitored and early booster immunizations considered in low responders.

Keyphrases

sars cov
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
multiple sclerosis
respiratory syndrome coronavirus
patient reported